INC Research Holdings, Inc. (SYNH)
(Delayed Data from NSDQ)
$47.27 USD
+0.56 (1.20%)
Updated May 3, 2019 04:00 PM ET
After-Market: $47.36 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$47.27 USD
+0.56 (1.20%)
Updated May 3, 2019 04:00 PM ET
After-Market: $47.36 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Abbott (ABT) Meets Q3 Earnings Estimates, Lowers EPS Guidance
by Zacks Equity Research
We are optimistic about Abbott's (ABT) strong and consistent EPD and Medical Devices performance organically.
QIAGEN (QGEN) Launches QIAseq FastSelect Technology Kits
by Zacks Equity Research
The launch of the kits is expected to bolster QIAGEN's (QGEN) Life Sciences Business Area
Thermo Fisher Gets a Boost from Buyouts and Global Expansion
by Urmimala Biswas
Thermo Fisher (TMO) registers a solid international performance with strong growth in Europe and Asia-Pacific including China.
QIAGEN Down on Dim Q3 Prelim Sales, Startling CEO Departure
by Zacks Equity Research
If the dismal preliminary sales performance was not enough, then the news pertaining to QIAGEN's (QGEN) current CEO Peer M. Schatz's stepping down came as another huge blow.
Smith & Nephew's (SNN) STITCH Study Outcome Encouraging
by Zacks Equity Research
This can be considered a major step in Smith & Nephew's (SNN) commitment toward strengthening its Global Sports Medicine and ENT segment.
Medtronic Gets FDA's Breakthrough Device Nod for Valiant TAAA
by Zacks Equity Research
This FDA designation is expected to bolster Medtronic's (MDT) Aortic, Peripheral & Venous line within the broader Cardiac and Vascular group.
SYNH vs. NXGN: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
SYNH vs. NXGN: Which Stock Is the Better Value Option?
Syneos Health (SYNH) Up 1.2% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Syneos Health (SYNH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks.com featured highlights include: Syneos, Carlisle, United Technologies, Ares Capital and Principal Financial
by Zacks Equity Research
Zacks.com featured highlights include: Syneos, Carlisle, United Technologies, Ares Capital and Principal Financial
Add These 5 Stocks With Solid Sales Growth to Your Portfolio
by Swayta Shah
Robust sales growth is the key to survival in today's fast changing and highly competitive operating backdrop.
SYNH or CERN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
SYNH vs. CERN: Which Stock Is the Better Value Option?
Are Investors Undervaluing Syneos Health (SYNH) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
3 Reasons Growth Investors Will Love Syneos Health (SYNH)
by Zacks Equity Research
Syneos Health (SYNH) could produce exceptional returns because of its solid growth attributes.
HMS Holdings (HMSY) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
HMS Holdings (HMSY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Here's Why You Should Invest in Cooper Companies Stock Now
by Zacks Equity Research
Cooper Companies (COO) is gaining traction from expansion in international markets, robust product portfolio across segments and prudent acquisitions.
Here's Why You Should Invest in HMS Holdings (HMSY) Stock Now
by Zacks Equity Research
HMS Holdings (HMSY) is gaining traction from the growing PI and TPM analytical services as well as robust margins.
SYNH or HMSY: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
SYNH vs. HMSY: Which Stock Is the Better Value Option?
Syneos Health (SYNH) Q2 Earnings Beat Estimates, '19 View Up
by Zacks Equity Research
We are upbeat about Syneos Health's (SYNH) strong year-over-year revenue growth across both operating segments.
Syneos Health (SYNH) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Syneos Health (SYNH) delivered earnings and revenue surprises of 5.71% and 1.60%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Syneos Health (SYNH) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Syneos Health (SYNH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SYNH vs. HMSY: Which Stock Is the Better Value Option?
by Zacks Equity Research
SYNH vs. HMSY: Which Stock Is the Better Value Option?
Why Is Syneos Health (SYNH) Up 4.6% Since Last Earnings Report?
by Zacks Equity Research
Syneos Health (SYNH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Syneos' (SYNH) Q1 Earnings Miss Estimates, Revenues In Line
by Zacks Equity Research
Syneos Health (SYNH) sees strong year-over-year revenue growth across both operating segments ??? Clinical Solutions and Commercial Solutions.
Syneos Health (SYNH) Misses Q1 Earnings Estimates
by Zacks Equity Research
Syneos Health (SYNH) delivered earnings and revenue surprises of -1.67% and 0.02%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Syneos Health (SYNH) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Syneos Health (SYNH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.